(TSHA) – Business Wire
-
GordonMD® Invests in Private Placement for Taysha Gene Therapies
-
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
-
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
-
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
-
Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference
-
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
-
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
-
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Acti
-
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event
-
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-12
-
Taysha Gene Therapies Added to the ICE Biotechnology Index
-
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
-
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease
-
Taysha Gene Therapies Added to the Nasdaq Biotechnology Index
-
Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLC
-
Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences
-
Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10
-
Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement Approach Demonstrating Therapeutic Potential for The Treatment of A
-
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit
-
Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Mari
-
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome
-
Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Cons
-
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
-
Taysha Gene Therapies to Participate in Upcoming October Investor Healthcare Conferences
-
Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome
-
Taysha Gene Therapies Announces Publication of Positive Preclinical Data for TSHA-104 Demonstrating Therapeutic Potential in SURF1-associated Leigh Syndrome in Journal Molecular Therapy: Methods &
-
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome
-
Taysha Gene Therapies to Participate in Upcoming September Investor Healthcare Conferences
-
Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency From the European Commission
-
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease
-
Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing
-
Taysha Gene Therapies to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 16
-
Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences
-
Taysha Gene Therapies to Host Manufacturing Day
-
Taysha Gene Therapies to Participate in Upcoming July Investor Healthcare Conference
-
Taysha Gene Therapies Announces Publication of Natural History Data for TSHA-120 in Giant Axonal Neuropathy in the Journal, Brain
-
Taysha Gene Therapies to Host Virtual R&D Day
-
Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum
-
Taysha Gene Therapies to Host First Annual Stockholder Meeting
-
Taysha Gene Therapies to Participate in Upcoming June Investor Healthcare Conferences
-
Taysha Gene Therapies Joins the Rare Disease Company Coalition
-
Taysha Gene Therapies Expands Leadership Team with the Appointment of Chief Development Officer
-
Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences
-
Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
-
Taysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Reviewed Journal
-
Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
Back to TSHA Stock Lookup
